ERBB2 and breast carcinoma: The results of the Phase 3 trial, PALOMA-2 (NCT01740427) were recently reported.15 Postmenopausal women with ER-positive, HER2-negative breast cancer were treated with palbociclib plus letrozole or placebo plus letrozole.